Companies

RNA-targeting therapeutics for oncology, agingDs, more; antisense oligonucleotide–based senolytics

drugs to boost natural cell defenses against damaging chemicals that arise naturally & accumulate w/ age

research labs to spin off new R&D to extend longevity; first in reprogramming, autophagy, microfluidics (BBB)

personalized mitochondrial medicines by drugging proteases of mito inner membrane

B2B antibodies for biomarkers of neuroDs: Aβ, tau, synuclein; for use in therapeutics development & trials

stem cell technology for health & longevity

selective mTORC1 inhibitors & CD38 inhibitors

ML on epigenetic datasets f/ biobanks for biomarkers & reports on epigenetic drug effects in clinical trials.

DTC education, coaching, & supplements (thru a partner) based on current anti-aging research

Connecting people to doctors willing to prescribe known aging drugs

allogeneic stem cells w/ tech for stable engraftment & low immunogenicity; tissue regeneration drugs

drug discovery based on sequencing antibodies of immune individuals, for cancer, neuroDs & infections

immuno-neurology: modulate immune system to cure dementias w/ based on insights from genetics

Preclinical biotechnology company developing selective small-molecule integrin antagonists to reduce collagen deposition and scar-tissue formation in fibrotic disease.

disrupt metabolic microenvironment of cancer & quasi-cancer cells for "multiple age-related diseases"

leads from blood proteins that go up or down with age, eg young blood fractions

Clinical-stage neurodegeneration company developing an oral iron chaperone designed to restore brain iron balance, reduce pathological alpha-synuclein aggregation, and preserve neuronal function.

augmented reality & AI mobile app 10min cognitive test, FDA cleared & covered by Medicare

cell rejuvenation by partial/epigenetic reprogramming; big & academic-like: aiming to be "Bell Labs" of bio

amplification of misfolded proteins for sensitive detection in CSF & blood, for αS (1st), Aβ, tau

healthy longevity for dogs focused on cell senescence & NAD

Preclinical biotechnology company developing oral small molecules that modulate pathological stress granules and biomolecular condensates to reduce protein aggregation in neurodegenerative disease.

Clinical-stage biopharmaceutical company using human genetics to develop therapies for neurological, inflammatory, and autoimmune disease, including a small-molecule CLEC16A program designed to modulate mitophagy and autophagy.

Biotechnology company using single-cell data to identify pathogenic cell populations and surface markers, then designing targeted biologics to selectively eliminate disease-driving cells.

Veterinary regenerative-medicine company providing autologous fat-derived cell therapy, platelet-rich plasma, and proactive stem-cell banking for dogs and cats.

in-vivo target screening with machine learning to age-related diseases

Clinical-stage biotechnology company developing cancer medicines that target DNA-damage response, replication stress, and DNA-repair dependencies.

personalized cell therapies: autologous iPSCs, 1st for neuron replacement for PD

allogeneic stem cells for neuro, inflammatory, immune, & CV diseases

drug platform for modulators of entering senescence, for aging (suppress) & cancer (stimulate)

Biotechnology company designing autophagy-targeting chimeric small molecules to selectively remove disease-causing proteins, aggregates, malfunctioning mitochondria, and other cellular components.

Biopharmaceutical company developing bifunctional degraders that route pathogenic extracellular and membrane proteins into endogenous endolysosomal degradation pathways.

Clinical-stage biotechnology company developing oral small molecules that modulate glycosphingolipid metabolism to address pathological metabolite accumulation and neurological disease in lysosomal storage disorders.

non-rapalog mTORC1 inhibitors using new site on mTOR, for aging & cancer (esp. glioblastoma)

human 20+yr biobanks + multiomics + AI drug platform

ECM-mimicing injectable scaffold for tissue regeneration

drug discovery platform for aging based on plant secondary metabolites

targeting muscle/bone, cognition, & cell senescence with a variety of paths to market

small molecule Wnt pathway modulation to target root causes of varied diseases, many age-related

AAV & CMV gene therapy to lengthen healthy lifespan, 1st for AD by restoring microglia & astrocyte function

universal pluripotent stem cell lines for allogeneic cell therapies for neuro-/cardio-/immunology

Clinical-stage biopharmaceutical company developing mitochondrial-targeted formulations of oxidized coenzyme Q10 for primary mitochondrial disease, sarcopenia, tissue repair, and oncology.

autologous stem cells for neuroDs: MSCs differentiated to secret more neurotrophic factors (NTFs)

control of metabolism for aging / age-related diseases

broad mission to improve health and longevity using technology to advance biological science

biopharma umbrella company focused on aging

autophagy drugs for neuro, inflammatory, metabolic, and muscle disorders

Swedish biotechnology company manufacturing donor-derived mesenchymal stem cells at scale for regulated clinical research and regenerative-medicine collaborations.

mitochondria transplantation 1st for ischemia-reperfusion injury then broader aging

reverse aging by affecting core biological mechanisms at the cellular level using multi-omics data

sells AgeMeter multimodal test of biological age (successor to H-SCAN test)

drug discovery platform by analyzing brain cell transcriptome diffs by age, cell type, region, & disease

nutraceuticals for aging, esp. flagship product Niagen w/ nicotinamide riboside (NR), an NAD+ precursor

senolytics, initially based on FOXO4-p53 interfering peptide

study rejuvenation in human iPSCs by force-aging them to understand rejuvenation & develop therapies

find mtDNA peptides (eg that decrease w/ age) & optimized analogs to treat metabolic dysfunction

Clinical-stage biotechnology company using computational protein-dynamics methods to discover oral small-molecule correctors and activators for genetically defined diseases caused by protein misfolding and impaired trafficking.

catalytic antibodies (catabodies) for aging (1st for ATTR & Aβ) & electrophilic vaccines (1st for HIV)

cyclodextrin derivatives to remove 7-ketocholesterol to remove arterial plaques

hydroxypropyl beta cyclodextrin for cholesterol transport for Alzheimer’s & Niemann-Pick Disease Type C1 (NPC)

improve mitochondria function by regulating fission & fusion

activate endogenous immune cells to clear senescent cells

drug discovery for neurodegeneration, optimized for brain delivery, guided by genetics & biomarkers

Clinical-stage biotechnology company discovering small molecules that modulate pathological biomolecular condensates, membraneless compartments that organize proteins, nucleic acids, signaling, transcription, and stress responses.

Canine-longevity research organization developing an intramuscular follistatin gene-therapy program intended to study arthritis and healthspan in aging dogs.

block cellular senescence

DTC biomarkers of systemic chronic inflammation based on Stanford 1000 immunomes project & AI

small molecule to make TTR stable to prevent ATTR: mimics bonds from a natural gene variant

Biotechnology company developing selective HDAC6 inhibitors to restore intracellular transport and proteostasis and address protein aggregation, mitochondrial dysfunction, inflammation, and fibrosis.

drug plattform for damaged elestin: particle design + elastin targeting for arterial diseases

recombinant GDF11, first for stroke

supplement called Basis: NR + pterostilbene for boosting NAD+; plus DTC epigenetic clock

devices to access & filter toxic proteins from CSF, 1st for ALS

Biotechnology company developing small-molecule modulators of the lysosomal transporters ATP13A2 and ATP10B to restore endo-lysosomal function in Parkinson's disease and other dementias.

endogenous regenerative medicine via drug discovery for regulation of endogenous stem/progenitor cells

Preclinical biotechnology company developing bifunctional small molecules that recruit deubiquitylases to stabilize, relocate, or alter the activity of beneficial proteins.

DTC Horvath methylation clock

Clinical-stage biopharmaceutical company developing oral 15-PGDH inhibitors that enhance endogenous PGE2 signaling to restore tissue homeostasis, stimulate regeneration and reduce fibrosis.

platform to identify drugs and combinations to safely extend healthy lifespan across multiple species

stimulating mitochondrial thermogenesis to treat metabolic disorders

comparative animal genomics & multi-omics for drug discovery to improve human health

Preclinical biotechnology company developing small molecules and antibodies intended to block fibroblast activation, matrix-stiffness signaling, and excessive collagen deposition in fibrotic kidney disease.

Biotechnology company using atom-by-atom drug design to develop small molecules that inhibit DRP1-mediated mitochondrial fragmentation and SARM1-mediated axonal degeneration.

discovery platform for small molecule modulators of cell reprogramming based on mechanobiology, imaging, ML

unbiased screening platform for new aging targets using AI, vision, & cellular model of aging hallmarks

drug platform using protein manufacturing tech, senolytics targeting p53 pathways (eg p53/FOXO4)

B2B epigenetic tests as a service (for pharma & nutraceutical clients, research, insurance)

Clinical-stage biotechnology company designing allosteric small molecules to stabilize, activate, destabilize, or degrade disease-implicated proteins, including restoration of lysosomal glucocerebrosidase function in Parkinson's disease.

Animal-health biotechnology company developing off-the-shelf allogeneic mesenchymal stromal-cell therapies for inflammatory and degenerative diseases in companion animals.

drug discovery platform for inflammatory & aging diseases; lead is p38α kinase inhibitor

Conboy & George Church startup: molecular noise biological age test; coming spring 2024

platform using naturally selected long-lived flies (drosophila) & genomics

gene therapies for aging in dogs & humans, especially relating to SIRT6

entolimod & other drugs for anti-aging & cancer, esp. by protecting genome, esp. against transposons

allotopic expression w/ targeting to deliver mRNA to mitochondria, for retinal & neuro mito diseases

physics based data/AI biomarkers for licensing & therapy development

pharmaceutical scerening platform to treat aging

Geroscience company developing company-described peptide and controllable gene-therapy platforms intended to target mitochondrial mechanisms of cellular aging and eliminate selected cell populations.

DTC aging clock based on glycans, sugar molecules that surround and modify proteins